-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

Benzinga·08/14/2026 19:52:29
语音播报
Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.